I'll put my 2 cents in neg. In the March quarterly released 2...

I'll put my 2 cents in neg. In the March quarterly released 2 months ago....


So I don't think this is a sales pitch in readiness for a CR. It would seem to be about 'educating' the industry and potential investors on the recent developments of Optiscan. If we go back just 12 months, so much as changed.

Having said that, the roadshow information clearly states predicted cash flow positive is five years away. I would assume at some point, with all the research and cash needed for the FDA submissions, a CR, or two, will be necessary. And perhaps you are right, it could be sooner rather than later. Hopefully the annual report will give you a better feel in that regard.